Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer / 中华肿瘤杂志
Chinese Journal of Oncology
; (12): 214-216, 2006.
Article
in Zh
| WPRIM
| ID: wpr-308379
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To detect changes of serum soluble Apo-1/Fas (sApo-1/Fas) in pancreatic cancer patients and to investigate its clinical value in assessing the effect of chemotherapy.</p><p><b>METHODS</b>The serum level of sApo-1/Fas in 30 normal control subjects and 58 pancreatic cancer patients were detected using enzyme-linked immunosorbent assay (ELISA), and the sApo-1/Fas level of 48 pancreatic cancer patients, before and after chemotherapy was compared.</p><p><b>RESULTS</b>Compared with the level of the control group, the level of serum soluble Apo-1/Fas was significantly correlated with clinical stage but not with age, sex or pathologic type of pancreatic cancer. It was elevated gradually from stage II to IV (P < 0.01). However, it would obviously decrease in pancreatic cancer patients after chemotherapy (P < 0.01).</p><p><b>CONCLUSION</b>The serum soluble Apo-1/Fas may be involved in the development of pancreatic cancer, and it may be used as one parameter to assess the disease status and prognosis of pancreatic cancer patient.</p>
Full text:
1
Index:
WPRIM
Main subject:
Pancreatic Neoplasms
/
Prognosis
/
Blood
/
Remission Induction
/
Antineoplastic Combined Chemotherapy Protocols
/
Cisplatin
/
Adenocarcinoma, Mucinous
/
Disease Progression
/
Fas Receptor
/
Carcinoma, Pancreatic Ductal
Type of study:
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Zh
Journal:
Chinese Journal of Oncology
Year:
2006
Type:
Article